167 related articles for article (PubMed ID: 2653518)
21. Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Orlandi E; Lazzarino M; Bernasconi P; Astori C; Bernasconi C
Haematologica; 1998 Aug; 83(8):758-9. PubMed ID: 9793267
[TBL] [Abstract][Full Text] [Related]
22. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
23. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
24. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
25. Late relapse after autologous BMT.
Salutari P; Micciulli G; Chiusolo P; Tommasi M; Di Mario A; Sica S; Leone G
Leukemia; 1996 May; 10(5):922-3. PubMed ID: 8656692
[No Abstract] [Full Text] [Related]
26. [Successful treatment of acute myelomonocytic leukemia developed from essential thrombocythemia with cytarabine plus etoposide].
Ishii Y; Goto A; Katagiri T; Miyazawa K; Ohyashiki K
Rinsho Ketsueki; 2004 Nov; 45(11):1211-3. PubMed ID: 15609690
[TBL] [Abstract][Full Text] [Related]
27. 11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone.
Ohshima A; Miura I; Chubachi A; Hashimoto K; Nimura T; Utsumi S; Takahashi N; Hayashi Y; Seto M; Ueda R; Miura AB
Am J Hematol; 1996 Dec; 53(4):264-6. PubMed ID: 8948668
[TBL] [Abstract][Full Text] [Related]
28. Modified BEAM conditioning regimen in patients with Hodgkin and non-Hodgkin lymphomas.
Hallack Neto AE; Borges dos Santos K; Atalla A
Exp Clin Transplant; 2012 Dec; 10(6):622. PubMed ID: 23216569
[No Abstract] [Full Text] [Related]
29. [Combined therapy with mitoxantrone and cytosine arabinoside as a first-line treatment in ANLL: preliminary results].
Angós JA; Gutiérrez M; Moreno JA; Aguado MJ; Romero MS
Sangre (Barc); 1993 Jun; 38(3):250-1. PubMed ID: 8211557
[No Abstract] [Full Text] [Related]
30. [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Chubachi A; Kuriya S; Narigasawa Y; Meguro K; Endo K; Takami H; Sato S; Sasaki H; Shiga T; Maruyama Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2101-6. PubMed ID: 8607622
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
32. Treatment of poor prognosis acute myeloid leukemia with aggressive and non-aggressive chemotherapy.
Stenke L; Hast R; Reizenstein P
Chemioterapia; 1987 Jun; 6(2 Suppl):723-4. PubMed ID: 3509530
[No Abstract] [Full Text] [Related]
33. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
35. A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia.
Canales MA; Arrieta R; Hernández-García C; Bustos JG; Aguado MJ; Hernández-Navarro F
Bone Marrow Transplant; 1999 Feb; 23(3):305. PubMed ID: 10084266
[No Abstract] [Full Text] [Related]
36. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
Glossmann JP; Josting A; Pfistner B; Paulus U; Engert A;
Ann Hematol; 2002 Aug; 81(8):424-9. PubMed ID: 12223998
[No Abstract] [Full Text] [Related]
37. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
Castagnola C; Nozza A; Corso A; Bernasconi C
Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
[TBL] [Abstract][Full Text] [Related]
38. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Salvucci M; Zanchini R; Molinari A; Zuffa E; Poletti V; Poletti G; Zaccaria A
Haematologica; 2000 Jul; 85(7):769-70. PubMed ID: 10897135
[No Abstract] [Full Text] [Related]
39. Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Kurrle E; Ehninger G; Fackler-Schwalbe E; Freund M; Heil G; Hoelzer D; Link H; Löffler B; Lösch A; Mitrou PS
Haematol Blood Transfus; 1990; 33():254-60. PubMed ID: 2182418
[No Abstract] [Full Text] [Related]
40. Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Kiss I; Tomasek J
Stem Cells; 1999; 17(4):233-4. PubMed ID: 10437987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
